XMT-1660: A Phase I, First-in-human Trial of a B7-H4-directed Dolasynthen Antibody-Drug Conjugate in Ovarian, Endometrial, and Breast Cancers
GYNECOLOGIC ONCOLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined